Scienture Corp (SCNX): Price-to-Projected Revenue Ratio

Corporate emblem and logo of Scienture Corp (SCNX)

Scienture Holdings Inc develops enhanced drug formulations in the US, leveraging patent protection. Experienced management is preparing the company for clinical trials. The business ensures high customer loyalty through deep software customization to meet regulatory standards. The company's expected P/S, illustrated in this chart on GURU.Markets, helps assess the asset's value, where 7.40 captures the current value of the indicator.

Scienture Holdings - SCNX Market Cap to Future Revenue Ratio (period 09/24/2024 - 11/16/2026)

Comprehensive metric breakdowns and analytics for scienture.com (SCNX)

Initial company analysis:SCNX (Scienture Holdings Inc.)
Product sample of Scienture Holdings Inc

To protect capital from volatility between earnings reports, it is crucial for investors to understand the premium the market is pricing into future sales. The optimization of therapeutic drug profiles at Scienture Holdings Inc (SCNX) reduces development risks, rendering the forward P/S ratio an accurate tool for valuing each dollar of expected revenue, which helps avoid overpaying for management and prevents asset freezes.

Who Scienture Holdings Inc competes with

Price-to-Projected Revenue Ratio Veeva Corp VEEV|Price to Expected Revenue Ratio DOCS (Doximity, Inc.)|HQY: Forward Price-to-Revenue Multiple|Forward Price to Sales WAY (waystar.com)|CorVel Corp. (CRVL) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Privia Health (PRVA)|Price-to-Projected Revenue Ratio Huron Corp|Market Cap to Projected Revenue CERT (Certara Corp)|Price-to-Projected Revenue Ratio Omnicell (OMCL)|GoodRx Holdings, Inc. - Market Cap to Projected Revenue|Schrödinger - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Phreesia Inc (PHR)|OMDA: Forward Price-to-Revenue Multiple|Forward Price to Sales EVH (Evolent Health, Inc.)|HSTM: Forward P/S Multiple|DH: Price to Expected Revenue Ratio|CCSI (Consensus) - Forward P/S Multiple|Price-to-Projected Revenue Ratio AGL|Forward P/S Multiple ABSI|Market Cap to Expected Sales Ratio So-Young Corp|Price-to-Projected Revenue Ratio National Research NRC|SPOK - Forward Price-to-Revenue Multiple|optimizerx.com - Forward P/S Multiple|Projected Price to Revenue TruBridge (TBRG)|SLP: Forward P/S Multiple|SOPH - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple HCAT|CCLD (CareCloud) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio researchsolutions.com (RSSS)|DLHC (DLH Holdings) - Forward Price to Sales|Price-to-Projected Revenue Ratio OneMedNet ONMD|Price to Expected Revenue Ratio HCTI (Healthcare Triangle Corp)|iSpecimen Corp - Forward P/S Multiple|Forward Price to Sales BFRG (bullfrogai.com)|WORX: Forward P/S Multiple|Forward Price-to-Revenue Multiple MSP Recovery|Price-to-Projected Revenue Ratio icoreconnect.com|MEDS: Forward Price to Sales|Price-to-Projected Revenue Ratio Orgenesis Inc. (ORGS)|Market Cap to Expected Sales Ratio R1 RCM, Inc.|Forward P/S Multiple SHCR (sharecare.com)|Market Cap to Expected Sales Ratio Streamline Health Solutions, Inc. (STRM)|SYRA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Apollo Medical Holdings Inc. AMEH|Model N (MODN) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue NXGN